Equities analysts forecast that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce $930,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $550,000.00 and the highest estimate coming in at $1.30 million. AcelRx Pharmaceuticals posted sales of $2.66 million during the same quarter last year, which would indicate a negative year over year growth rate of 65%. The business is expected to report its next earnings report on Tuesday, August 7th.
On average, analysts expect that AcelRx Pharmaceuticals will report full year sales of $6.35 million for the current financial year, with estimates ranging from $1.99 million to $10.70 million. For the next year, analysts forecast that the business will post sales of $23.07 million per share, with estimates ranging from $17.40 million to $28.74 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.78 million.
NASDAQ ACRX traded up $0.23 on Monday, reaching $4.13. 994,112 shares of the company’s stock traded hands, compared to its average volume of 503,621. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a debt-to-equity ratio of -0.20, a current ratio of 4.05 and a quick ratio of 4.00. The stock has a market capitalization of $187.32 million, a P/E ratio of -3.75 and a beta of 2.36.
Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of AcelRx Pharmaceuticals in the first quarter worth approximately $113,000. Virtu Financial LLC bought a new position in shares of AcelRx Pharmaceuticals in the fourth quarter worth approximately $120,000. Northern Trust Corp grew its holdings in shares of AcelRx Pharmaceuticals by 60.8% in the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock worth $192,000 after purchasing an additional 34,584 shares during the last quarter. Finally, Geller Family Office Services LLC grew its holdings in shares of AcelRx Pharmaceuticals by 175.0% in the fourth quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock worth $557,000 after purchasing an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 8.40% of the company’s stock.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.